Better A1C, weight seen with canagliflozin treatment

04/15/2013 | MedWire News (U.K.)

Type 2 diabetes patients who used canagliflozin as an add-on to metformin/sulfonylurea treatment showed better A1C levels and body weight at 52 weeks than those who took sitagliptin, according to a study in Diabetes Care. Researchers also found 47.6% of canagliflozin-treated patients attained an A1C of less than 7%, compared with 35.3% in the sitagliptin group.

View Full Article in:

MedWire News (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY